Q2 Sequential Improvement Guidance
Management expects a clear sequential improvement in Q2 versus Q1 and provided a quantitative corridor for Q2 EBITDA contribution of EUR 130 million to EUR 150 million, highlighting stronger volumes and/or pricing as drivers.
Full-Year Guidance Maintained
Despite geopolitical uncertainty (Middle East), LANXESS did not change its full‑year guidance and indicated upside potential if Q2 momentum continues.
Pricing Actions Being Implemented
Company announced early price increases (March) to mitigate input cost inflation; rollout expected to ramp: initial impact in April, ~2/3 effect in May and full effect by June, with further impacts on contract pricing into Q3.
Improving Volume Momentum in March/April
Volumes were lower in January–February but showed recovery in March and a slight uptick in April and May with reasonable visibility into April sales and order book for May.
Tight Working Capital and Stable Net Debt
Management emphasized tight net working capital (lower than prior year) and disciplined cash management; typical net debt seasonality is an increase of around EUR 100–200 million at the beginning of the year, but net debt was kept at a comparable level.
Segment & Market Opportunities (Advanced Intermediates, Additives, Crop Protection)
Management highlighted material upside in Advanced Intermediates driven by customers prioritizing delivery security and rising China chemical prices; additives show moderate upside; Saltigo (crop protection/APIs) may benefit if customers rotate away from some Asian generics due to supply/freight pressures.
Bromine Price Level Improved vs Prior Years
Although bromine spot prices fell from a recent spike, the current level (~EUR 38,000–40,000/t) is substantially higher versus depressed levels a year or two ago (management noted ~100% higher than 1–2 years ago).